Priority review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced

Read the full 212 word article

User Sign In